Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.13)
# 1,206
Out of 4,967 analysts
492
Total ratings
42.92%
Success rate
1.85%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Downgrades: Neutral | $1 | $0.87 | +14.93% | 17 | Aug 29, 2025 | |
| EVO Evotec SE | Maintains: Buy | $8 → $7 | $3.40 | +105.88% | 10 | Aug 14, 2025 | |
| BHVN Biohaven | Maintains: Buy | $54 → $30 | $15.89 | +88.80% | 15 | Aug 12, 2025 | |
| EOLS Evolus | Maintains: Buy | $27 → $20 | $7.51 | +166.31% | 28 | Aug 6, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $31 | $16.34 | +89.72% | 1 | Aug 6, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $105 → $115 | $44.73 | +157.13% | 25 | Aug 5, 2025 | |
| ARGX argenx SE | Maintains: Buy | $720 → $774 | $706.41 | +9.57% | 40 | Aug 1, 2025 | |
| ALKS Alkermes | Reiterates: Neutral | $46 | $29.40 | +56.46% | 24 | Jul 21, 2025 | |
| IRON Disc Medicine | Reiterates: Buy | $118 | $61.58 | +91.62% | 16 | Jul 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Buy | $81 | $33.30 | +143.24% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $12.39 | +45.28% | 20 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $1.45 | +1,624.14% | 26 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $58.83 | +35.99% | 33 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $39.30 | +34.86% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.19 | +488.24% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $7.17 | +95.26% | 17 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $19.15 | +77.55% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $15.32 | +24.02% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.03 | +491.13% | 17 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.51 | +226.98% | 14 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 | $15.07 | +238.42% | 22 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.74 | +934.48% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $57 | $28.17 | +102.34% | 26 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $13.84 | +8.38% | 15 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.31 | +116.45% | 14 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.74 | +48,352.22% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.08 | +825.93% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $177.84 | +2.34% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.14 | +162.61% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $36.69 | -50.93% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $18.75 | -57.33% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $27.22 | +91.04% | 2 | Jun 11, 2019 |
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: $1
Current: $0.87
Upside: +14.93%
Evotec SE
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.40
Upside: +105.88%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $54 → $30
Current: $15.89
Upside: +88.80%
Evolus
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $7.51
Upside: +166.31%
Rapport Therapeutics
Aug 6, 2025
Initiates: Buy
Price Target: $31
Current: $16.34
Upside: +89.72%
Praxis Precision Medicines
Aug 5, 2025
Maintains: Buy
Price Target: $105 → $115
Current: $44.73
Upside: +157.13%
argenx SE
Aug 1, 2025
Maintains: Buy
Price Target: $720 → $774
Current: $706.41
Upside: +9.57%
Alkermes
Jul 21, 2025
Reiterates: Neutral
Price Target: $46
Current: $29.40
Upside: +56.46%
Disc Medicine
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $61.58
Upside: +91.62%
Crinetics Pharmaceuticals
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $33.30
Upside: +143.24%
Jun 18, 2025
Reiterates: Buy
Price Target: $18
Current: $12.39
Upside: +45.28%
Jun 11, 2025
Reiterates: Buy
Price Target: $25
Current: $1.45
Upside: +1,624.14%
Jun 3, 2025
Reiterates: Buy
Price Target: $80
Current: $58.83
Upside: +35.99%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $39.30
Upside: +34.86%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.19
Upside: +488.24%
Apr 28, 2025
Reiterates: Buy
Price Target: $14
Current: $7.17
Upside: +95.26%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $19.15
Upside: +77.55%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $15.32
Upside: +24.02%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $2.03
Upside: +491.13%
Mar 20, 2025
Reiterates: Buy
Price Target: $18
Current: $5.51
Upside: +226.98%
Mar 19, 2025
Reiterates: Buy
Price Target: $51
Current: $15.07
Upside: +238.42%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.74
Upside: +934.48%
Mar 3, 2025
Reiterates: Buy
Price Target: $57
Current: $28.17
Upside: +102.34%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $13.84
Upside: +8.38%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $2.31
Upside: +116.45%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.74
Upside: +48,352.22%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.08
Upside: +825.93%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $177.84
Upside: +2.34%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.14
Upside: +162.61%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $36.69
Upside: -50.93%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $18.75
Upside: -57.33%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $27.22
Upside: +91.04%